Results 11 to 20 of about 7,827 (211)
Research progress on the clinical application of esketamine [PDF]
Esketamine is the S-enantiomer of racemic ketamine, which has a similar pharmacological mechanism to ketamine. Esketamine has the advantages of fast onset, fast metabolism, little impact on circulatory and respiratory functions, and strong sedative and ...
JIANG Lele, DU Xiaoxuan
doaj +2 more sources
Case report: two cases of rhabdomyolysis following esketamine treatment [PDF]
Major depressive disorder is a mental disorder affecting millions of people worldwide. A considerable proportion of patients demonstrate a lack of response to conventional treatment.
René Zeiss +3 more
doaj +3 more sources
The use of intraoperative sub-anesthetic esketamine for postoperative analgesia is controversial. In this study, the impact of sub-anesthetic esketamine on postoperative opioid self-administration was determined.
Hongyu Zheng +5 more
doaj +2 more sources
Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment [PDF]
Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression.
Jolien K.E. Veraart +4 more
openaire +4 more sources
Xu Zeng,1,2 Xianjie Zhang,2 Wencai Jiang,2,* Xinyu Zhou1,* 1Department of Anaesthesiology, Chengdu Medical College, Chengdu, People’s Republic of China; 2Department of Anesthesiology, People’s Hospital of Deyang City, Deyang, People’s Republic of
Zeng X, Zhang X, Jiang W, Zhou X
doaj +1 more source
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly
C. Gastaldon +3 more
doaj +1 more source
Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed +5 more
doaj +1 more source
Background: Because it has been reported that racemic ketamine had a local anesthetic-sparing effect when used for epidural analgesia this would suggest the likelihood of a potential advantage (less pruritus) over opioid drugs.
Siwen Lou +5 more
doaj +1 more source
Background Esketamine, an N-methyl-D-aspartate receptor antagonist, is commonly used for anesthesia and analgesia clinically. It was reported to negatively regulate cell proliferation, metastasis and apoptosis in cancer cells, including lung cancer and ...
Chao Li +3 more
doaj +1 more source
Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
Introduction Major depressive disorder is one of the most common and disabling mental disorders. More than 30% of individuals do not achieve remission after several trials of antidepressants and treatment-resistant depression (TRD) is associated with ...
M. D. R. D. R. F. D. A. Basto +4 more
doaj +1 more source

